WILSON JOHN S 4/A
4/A · BOND LABORATORIES, INC. · Filed Nov 26, 2012
Insider Transaction Report
Form 4/AAmended
BOND LABORATORIES, INC.BNLB.OB
WILSON JOHN S
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Purchase
Common Stock
2012-11-06+1,399,352→ 2,649,006 total
Holdings
- 332,500
Warrant
Exercise: $0.30Exp: 2015-11-15→ Common Stock (332,500 underlying) - 500,000
Stock Option
Exercise: $0.10From: 2011-06-08Exp: 2021-06-08→ Common Stock (500,000 underlying) - 500,000
Stock Option
Exercise: $0.09From: 2012-05-09Exp: 2017-04-13→ Common Stock (500,000 underlying) - 1,000,000
Warrant
Exercise: $0.15From: 2008-12-31Exp: 2013-12-31→ Common Stock (1,000,000 underlying) - 16.7
Series C Convertible Preferred Stock
Exercise: $0.25→ Common Stock (668,000 underlying)
Footnotes (5)
- [F1]Mr. Wilson acquired the shares of Common Stock and 8.76 shares of the Issuer's 10% Cumulative Perpetual Series B Preferred Stock for aggregate consideration of $50,000 in a private transaction.
- [F2]The Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock ("Series C Preferred") contains a provision preventing the conversion of the Series C Preferred if, as a result of such conversion, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 4.99% of the Issuer's Common Stock issued and outstanding.
- [F3]The Series C Preferred are perpetual.
- [F4]Each share of Series C Preferred is convertible into that number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing $10,000 per share (the liquidation preference) by the conversion price then in effect, or $.25 on the date of this Report. Conversion of the Series C Preferred is subject to the limitation on conversion described in Note 2.
- [F5]The Warrant contains a provision preventing the exercise of the Warrant if, as a result of such exercise, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 9.99% of the Issuer's Common Stock issued and outstanding.